Connect Biopharma Holdings Limited (CNTB)
NASDAQ: CNTB · Real-Time Price · USD
0.8979
-0.0291 (-3.14%)
At close: Oct 5, 2026, 4:00 PM EDT
0.8902
-0.0077 (-0.86%)
After-hours: Oct 5, 2026, 7:58 PM EDT
Connect Biopharma Holdings Employees
Connect Biopharma Holdings had 64 employees as of December 31, 2025. The number of employees increased by 2 or 3.23% compared to the previous year.
Employees
64
Change (1Y)
2
Growth (1Y)
3.23%
Revenue / Employee
$46,141
Profits / Employee
-$1,077,984
Market Cap
56.54M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 64 | 2 | 3.23% |
| Dec 31, 2024 | 62 | -19 | -23.46% |
| Dec 31, 2023 | 81 | -19 | -19.00% |
| Dec 31, 2022 | 100 | -8 | -7.41% |
| Jan 1, 2022 | 108 | 46 | 74.19% |
| Dec 31, 2020 | 62 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Clene | 79 |
| MindWalk Holdings | 77 |
| Xilio Therapeutics | 76 |
| Mereo BioPharma Group | 39 |
| eXoZymes | 32 |
| Boundless Bio | 28 |
| INmune Bio | 21 |
| MiNK Therapeutics | 15 |
CNTB News
- 4 days ago - 3 Penny Stocks on Investors’ Radar, October 1 - TipRanks
- 5 days ago - Why Is Penny Stock Connect Biopharma (CNTB) Up 98% Today? - TipRanks
- 5 days ago - Connect Biopharma Holdings Transcript: Study result - Transcripts
- 5 days ago - Connect Biopharma Holdings Press release: Study result - Filings
- 5 days ago - Connect Biopharma Holdings Slides: Study result - Filings
- 5 days ago - Connect Biopharma announces results from global Phase 2 study of rademikibart - TheFly
- 5 days ago - Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation - GlobeNewsWire
- 13 days ago - Connect Biopharma price target lowered to $5 from $8 at Oppenheimer - TheFly